Rallybio's TMDD Model Advances Safe Drug Development for Pregnant Women and FNAIT

Innovative Approaches in Drug Development for Pregnant Women: Rallybio's TMDD Model

Rallybio Corporation, a clinical-stage biotechnology company focused on therapies for rare diseases, makes strides in ensuring the safety of drug therapies for pregnant women. The company recently publishes a manuscript in Clinical Pharmacology and Therapeutics: Pharmacometrics & Systems Pharmacology, detailing their work on a target-mediated drug disposition (TMDD) model for RLYB212, a human monoclonal anti-HPA-1a antibody. This innovative approach aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition resulting from maternal alloimmunization. Dr. Steven Ryder, Rallybio’s Chief Medical Officer, underscores the critical need for safe dosage selection in clinical trials involving pregnant women, a demographic historically underrepresented in pharmacological research.

The TMDD model developed by Rallybio incorporates the dynamic physiological changes that occur during pregnancy, which are essential for determining appropriate dosing regimens. This model informs the ongoing Phase 2 dose confirmation trial for RLYB212, specifically targeting pregnant women at elevated risk for HPA-1a alloimmunization. By utilizing comprehensive simulations to analyze clearance rates and volume adjustments, Rallybio enhances its understanding of the drug's pharmacokinetics in this unique population. This meticulous approach not only aims to support the RLYB212 program but also signifies a broader commitment to utilizing model-informed drug development strategies that prioritize the safety and efficacy of monoclonal antibodies in pregnancy.

Rallybio also conducts a non-interventional study to assess the frequency of HPA-1a alloimmunization across a diverse population. As of November 1, 2024, over 13,000 pregnant women have been screened for this study, contributing valuable contemporary data. This extensive research effort reflects Rallybio's dedication to addressing the complexities of drug therapy in vulnerable populations, ultimately working to ensure the health and well-being of both mothers and their infants.

In addition to the TMDD model's implications for RLYB212, the company's research highlights a critical gap in pharmacological studies related to pregnant women. By advancing knowledge in this area, Rallybio not only seeks to enhance treatment options for FNAIT but also paves the way for future innovations in the safe administration of therapies during pregnancy.